September 18, 2012 SUBJECT: Combined Synopsis/Solicitation for Commercial Supplies This is a combined synopsis/solicitation for commercial supplies prepared in accordance with the format in Subpart 12.6 and Far Part 13 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued. This is a request for competitive quotes, and all offers received prior to September 25, 2012 will be considered by the Government. The solicitation is being issued as Request for Quote # VA260-12-Q-1686. The NAICS Code is 325413. This solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2005-61. Only emailed requests received directly from the requester are acceptable. Evaluation Factors: The Government will award based on Lowest Price Technically Acceptable (LPTA). An award will be made on the basis of the lowest price of quotes meeting the brand names salient characteristic as described in the schedule of items. Description: Various Ventana Histology Immunostainer Reagents and consumables to operate Ventana Instruments. Estimated usage is as follows. Quantity Net as values Quantities Price Totals VA MEDICAL CNTR-SEATTLE WA (2481) IHC Detection 760-500 - ULTRAVIEW UNIVERSAL DAB DETECTION KIT 15 IHC Detection 15 IHC Primary Antibodies - VentanaDx 790-2951 - ASSY; KIT PACK; PATHWAY C-KIT 2 IHC Primary Antibodies - VentanaDx 2 IHC Primary Antibodies - Other 760-2680 - FITC ANTI-IGG PRIMARY ANTIBODY 2 760-2681 - NEXES REAGENT, VENTANA, FITC ANTI-IGA 2 760-2682 - FITC ANTI-IGM PRIMARY ANTIBODY 2 760-2683 - FITC ANTI-KAPPA PRIMARY ANTIBODY 1 760-2684 - FITC ANTI-LAMBDA PRIMARY ANTIBODY 1 760-2685 - FITC ANTI-FIBRINOGEN PRIMARY ANTIBODY 1 760-2686 - FITC ANTI-C3 PRIMARY ANTIBODY 2 760-2688 - FITC ANTI-C1Q PRIMARY ANTIBODY 1 760-2699 - FITC ANTI-ALBUMIN PRIMARY ANTIBODY 1 760-1029 - CONFIRM NEG. CONTR. RABBIT IG 2 760-2014 - NEGATIVE CONTROL MOUSE IG 3 760-2504 - CONFIRM ANTI-CD15 (MMA) PAB, IVD 2 760-2505 - CONFIRM ANTI-CD45 (LCA) (RP2/18) PRIMARY ANTIBODY 2 760-2507 - ANTI-CEA (TF-3H8-1) PAB 1 760-2511 - ANTI-CD43 (L60) PRIMARY ANTIBODY 2 760-2513 - CONFIRM ANTI-DESMIN (DE-R-11) PAB 1 760-2531 - CONFIRM ANTI-CD20 (L26) PAB 5 760-2595 - ANTI-KERATIN, PAN (AE1/AE3 & PCK26) PAB 3 760-2224 - CELL MARQUE, Cytokeratin 7 (OV-TL 12/30) 1 760-2616 - CELL MARQUE, CD23 2 760-2625 - CELL MARQUE, CD56 1 760-2631 - CELL MARQUE, CD99,MIC2 1 760-2635 - CELL MARQUE, CYTOKERATIN 20 1 760-2636 - CELL MARQUE, CK, 34BETAE12 2 760-2642 - CELL MARQUE, FACTOR 8-R AG. 1 760-2645 - CELL MARQUE, HELICOBACTER PYLORI 4 760-2648 - CELL MARQUE, HSV I & II 1 760-2659 - CELL MARQUE, MYELOPEROXIDASE 1 760-2661 - CELL MARQUE, NEUROFILAMENT 1 760-2668 - CELL MARQUE, SYNAPTOPHYSIN 1 760-2705 - NEXES REAGENT, CELL MARQUE, CD10 2 760-4240 - Cell Marque, bcl-2 (124) 2 760-4241 - Cell Marque, bcl-6 2 760-4244 - Cell Marque, CD1a (MTB1) 1 760-4246 - Cell Marque, CD31 (1A10) 1 760-4248 - CD-138 (B-A38) 4 760-4257 - Cell Marque, Glycophorin A 1 760-4259 - Cell Marque, EMA (E29) 1 760-4264 - Cell Marque, MLH-1 (G16B-728) 1 760-4265 - Cell Marque, MSH-2 1 760-4270 - Cell Marque, PAX-5 (24) 2 760-4271 - Cell Marque, PSA (ER-PR8) 1 760-4276 - Cell Marque, Tryptase (G3) 1 760-4280 - CELL MARQUE, CD5 (SP19) 2 760-4282 - Cell Marque, Cyclin D1 (SP4) 1 760-4345 - Glial Fibrillary Acidic Protein (EP672Y) Primary Antibody 1 760-4380 - CDX-2 (EPR2764Y) PAb, Cell Marque 1 790-2914 - CONFIRM ANTI-S100 (4C4.9) PRIMARY ANTIBODY 2 790-2917 - CONFIRM ANTI-VIMENTIN (V9) PRIMARY ANTIBODY 2 790-2918 - CONFIRM ANTI-ALK1 (ALK01) 1 790-2926 - CONFIRM ANTI-CD30 (CLONE BER-H2) PRIMARY ANTIBODY 2 790-2927 - CONFIRM ANTI-CD34 (QBEND/10) PRIMARY ANTIBODY 2 790-2931 - CONFIRM ANTI-CD68 (KP-1) PRIMARY ANTIBODY 2 790-2990 - CONFIRM MART-1/MELAN A (A103) PRIMARY ANTIBODY 1 790-4341 - CONFIRM ANTI-CD3 (2GV6) RABBIT MONOCLONAL PRIMARY ANTIBODY 4 IHC Primary Antibodies - Other 92 IHC Ancillaries 760-080 - AMPLIFICATION KIT, CE 6 760-2018 - PROTEASE 1 2 760-2021 - HEMATOXYLIN 15 760-2037 - BLUING REAGENT 16 783-2855 - Prep Kit #5, BenchMark 1 771-751 - NEXES REAGENT DISPENSER CARD, OPTION #1 10 1358501 - LABEL, BLANK, FLAP, ROLL (540) 8 IHC Ancillaries 58 BenchMark Ancillaries 650-010 - LCS 48 950-300 - REACTION BUFFER CONCENTRATE (10X) 25 950-124 - CELL CONDITIONING SOLUTION, CC1, 2L 9 950-102 - 10X EZ PREP SOLUTION; 2L 11 BenchMark Ancillaries 93 Breast Business 790-4286 - CONFIRM ANTI-KI-67 (30-9) RABBIT MONOCLONAL PRIMARY ANTIBODY 3 Breast Business 3 IHC 263 VA MEDICAL CNTR-SEATTLE WA (2481) 263 Period of Performance: October 1, 2012 through September 30, 2013. The supplies and reagents used for this request are used in the Ventana Immunostainer Benchmark XT instrument. The immunostain process applies antibodies to tissue during the immunhistochemistry application. It defines tumor and other situations within cells of Veteran patients. This process is necessary to determine illness or disease. The offeror shall provide documentation detailing the specifications of the product being offered as to how it meets the salient characteristics. To the maximum extent practicable, offerors are encouraged to respond to this solicitation using pre-existing materials (such as brochures, catalogs, marketing documents) rather than creating new documents. Offerors shall annotate the salient characteristics listed above to indicate the location of the relevant information used to meet the specification (document name and page number). The VISN 20 Network Contracting Activity intends to solicit quotes and award a firm fixed price contract under full and open competition. The following clauses and provisions apply to this solicitation: 52.211-6 Brand Name or Equal; 52.212-1 Instructions to Offerors-Commercial; 52.212-2 Evaluation-Commercial Items; 52.212-3 Offeror Representations and Certifications-Commercial Items. 52.212-4, Contract Terms and Conditions-Commercial Items; 52.212-5, Contract Terms and Conditions Required To Implement Statutes or Executive Orders-Commercial Items, paragraph (a) and the following clauses in paragraph (b): 52.204-10 Reporting Executive Compensation & First-Tier Subcontract Award; 52.209-10 Prohibition on Contracting with Inverted Domestic Corporations; 52.219-28 Post Award Small business Program Representation; 52.222-3 Convict Labor; 52.222-19 Child Labor-Cooperation with Authorities and Remedies; 52.222-21, Prohibition of Segregated Facilities; 52.222-26 Equal Opportunity; 52.222-35 Equal Opportunity for Veterans; 52.222-36 Affirmative Action for Workers with Disabilities; 52.222-37 Employments Reports on Veterans; 52.223-18 Contractor Policy to Ban Text Messaging while Driving; 52.225-3 Buy American Act-Free Trade Agreement-Israeli Trade Act (iii) Alternate III; 52.225-13 Restrictions on Certain Foreign Purchases; and 52.232-34 Payment by Electronic Funds Transfer. 852.203-70 Commercial Advertising; 852.211-73 Brand Name or Equal; 852.237-70 Contractor responsibilities, 852.246-70 Guarantee, 852.246-71 Inspection; and 852.273-76 Electronic Invoice Submission. Offerors are to submit pricing to Department of Veterans Affairs Network Contracting Office 20 (NCO 20). Process of determining contract award: award will be to the lowest-priced responsive, responsible bidder who can provide the item. This information should be specific, concise, and complete and provide sufficient information to demonstrate the offeror's capacity to meet or exceed the requirements of the contract. The information required in provisions 52.212-1, 52.212-2, a completed copy of provisions 52.212-3, Offeror Representations and Certifications, Commercial Items. The full text of the referenced FAR clauses may be accessed electronically at https://www.acquisition.gov/far/. Quotes, including price and technical data for equal items, must be received by 5:00 PM, September 24, 2012 PT. Quotes shall be submitted via email to [email protected].

Bid Protests Not Available